优化FAPI同源二聚体用于诊疗一体化:连接子设计对DOTAGA.Glu2.(FAPI)2与DOTAGA.PEG2.Glu.(FAPI)2的影响
本研究评估了两种新型FAPI同源二聚体DOTAGA.Glu2.(FAPI)2和DOTAGA.PEG2.Glu.(FAPI)2的成像性能、肿瘤滞留及治疗潜力,分别用镓-68和镥-177标记。结果显示DOTAGA.Glu2.(FAPI)2具有更优的肿瘤滞留、药代动力学及治疗效果,支持其临床转化潜力。
要点
- DOTAGA.Glu2.(FAPI)2较DOTAGA.PEG2.Glu.(FAPI)2肿瘤滞留更优,96小时摄取值分别为4.2±0.5与1.2±0.02%I.A./g。
- DOTAGA.Glu2.(FAPI)2肿瘤半衰期显著延长(44.5 vs. 19小时),肿瘤暴露量AUC高2倍(971±74 vs. 542±28%I.A.×h/g)。
- 分次放射性配体治疗联合依维莫司进一步抑制肿瘤生长并改善生存。
核心结论
- DOTAGA.Glu2.(FAPI)2具有更优的肿瘤滞留、良好的药代动力学和增强的治疗效果,支持其临床转化潜力。
研究设计与样本
- 研究将DOTAGA.Glu2.(FAPI)2和DOTAGA.PEG2.Glu.(FAPI)2分别用镓-68和镥-177标记,进行体外实验(亲脂性、蛋白结合、饱和结合、内化与外化)和PC3小鼠体内评估(生物分布、代谢稳定性、血液与器官清除、PET/SPECT/CT成像及放射自显影),并用[177Lu]Lu-DOTAGA.Glu2.(FAPI)2进行分次放射配体治疗评估疗效。
主要发现
- 所有放射性配体放射化学纯度>99%,FAP亲和力高(Kd:0.9-1.5 nM),亲水性(LogDoctanol/PBS ≤-3),蛋白结合低(<10%)。
- 68Ga标记示踪剂肿瘤摄取持续至注射后3小时(>14%I.A./g),肿瘤与器官比值递增。
- 177Lu标记类似物初始摄取相当(4小时约15%I.A./g),[177Lu]Lu-DOTAGA.Glu2.(FAPI)2在96小时滞留优于[177Lu]Lu-DOTAGA.PEG2.Glu.(FAPI)2(4.2±0.5 vs. 1.2±0.02%I.A./g)。
- DOTAGA.Glu2.(FAPI)2血液清除快速双相,动力学更快;肿瘤半衰期显著延长(44.5 vs. 19小时),肿瘤暴露量高2倍(AUC:971±74 vs. 542±28%I.A.×h/g)。
- 成像证实高肿瘤/背景比值,放射自显影显示瘤内FAP分布异质;分次治疗显著抑制肿瘤生长并改善生存,联合依维莫司进一步增强。
临床怎么用
- DOTAGA.Glu2.(FAPI)2因肿瘤滞留和药代动力学优势,可作为FAP靶向诊疗一体化的候选化合物进一步临床转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the imaging performance, tumor retention, and therapeutic potential of two new FAPI homodimers, DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2, specifically designed to improve FAP-targeted tumor retention. METHODS: DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2 were radiolabeled with gallium-68 and lutetium-177. In vitro studies included lipophilicity, protein binding, saturation binding, internalization and externalization using FAP+ CAFs. In vivo evaluation in PC3-mice comprised biodistribution, metabolic stability, blood and organ clearance, PET/SPECT/CT imaging, and autoradiography. Therapeutic efficacy was assessed using fractionated radioligand therapy with [177Lu]Lu-DOTAGA.Glu2.(FAPI)2, as monotherapy or combined with everolimus. RESULTS: All radioligands showed > 99% radiochemical purity, high FAP affinity (Kd: 0.9-1.5 nM), hydrophilic profiles (LogDoctanol/PBS ≤-3), and low protein binding (< 10%). They exhibited high internalization and low externalization (~ 20% for [177Lu]Lu-DOTAGA.Glu2.(FAPI)2 and ~ 35% for [177Lu]Lu-DOTAGA.PEG2.Glu.(FAPI)2). The 68Ga-labeled radiotracers displayed sustained tumor uptake up to 3 h p.i. (> 14%I.A./g) with increasing tumor-to-organ ratios. For the 177Lu-labeled analogues the initial uptake was comparable (~ 15%I.A./g at 4 h p.i.), with [177Lu]Lu-DOTAGA.Glu2.(FAPI)2, showing even improved retention compared to [177Lu]Lu-DOTAGA.PEG2.Glu.(FAPI)2 (4.2 ± 0.5 vs. 1.2 ± 0.02%I.A./g at 96 h). Blood clearance was rapid and biphasic, with faster kinetics for DOTAGA.Glu2.(FAPI)2. For the same compound, tumor half-life was significantly prolonged (44.5 vs. 19 h), resulting in 2-fold higher tumor exposure (AUC: 971 ± 74 vs. 542 ± 28%I.A.×h/g). Imaging confirmed high tumor-to-background ratios, while autoradiography revealed heterogeneous intratumoral FAP distribution. Fractionated therapy significantly inhibited tumor growth and improved survival, further enhanced by everolimus. CONCLUSION: DOTAGA.Glu2.(FAPI)2 demonstrates superior tumor retention, favorable pharmacokinetics, and enhanced therapeutic efficacy, supporting its potential for clinical translation.
引用
- Kumar N, Bilinska A, Menéndez E, et al. Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2. Eur J Nucl Med Mol Imaging. 2026. PMID: 42448891. doi:10.1007/s00259-026-08078-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。